AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.

In fact, the signs over the last few months point to a company forging ahead in spite of the probe that ensnared current and former employees and led to the detention of AstraZeneca’s then China chief ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their ...

According to Leon Wang, President of Huawei's Data Communication Product Line, “AI WAN comprehensively empowers IP networks using AI in the Net5.5G era.” To understand why AI is essential to IP ...

Learn More » AstraZeneca's shares fell off a cliff late last year when it announced the arrest of some of its executives in China, including Leon Wang, the drugmaker's president in the country.